{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:59:49Z","timestamp":1773849589800,"version":"3.50.1"},"reference-count":25,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1055\/a-2216-5263","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T23:55:17Z","timestamp":1700697317000},"page":"595-597","source":"Crossref","is-referenced-by-count":2,"title":["Guided Anti-P2Y12 Therapy in Patients Undergoing Percutaneous Coronary Intervention"],"prefix":"10.1055","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7343-4534","authenticated-orcid":false,"given":"Marco","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"Divisione di Medicina Generale II, ASST Santi Paolo e Carlo, Dipartimento di Scienze della Salute, Universit\u00e0 degli Studi di Milano, Milan, Italy"},{"name":"Fondazione Arianna Anticoagulazione, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5705-2897","authenticated-orcid":false,"given":"Alessandro","family":"Squizzato","sequence":"additional","affiliation":[{"name":"Research Center on Thromboembolic Disorders and Antithrombotic Therapies, ASST Lariana, University of Insubria, Como, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Birocchi","sequence":"additional","affiliation":[{"name":"Divisione di Medicina Generale II, ASST Santi Paolo e Carlo, Dipartimento di Scienze della Salute, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1791-8905","authenticated-orcid":false,"given":"Gian Marco","family":"Podda","sequence":"additional","affiliation":[{"name":"Divisione di Medicina Generale II, ASST Santi Paolo e Carlo, Dipartimento di Scienze della Salute, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1055\/a-2177-4220","article-title":"Strategies for tailored antiplatelet therapy after percutaneous coronary intervention: unraveling complexities, embracing nuances","volume":"124","author":"D Landolina","year":"2024","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1055\/a-2149-4344","article-title":"Guided anti-P2Y12 therapy in patients undergoing PCI: three systematic reviews with meta-analyses of randomized controlled trials with homogeneous design","volume":"124","author":"S Birocchi","year":"2024","journal-title":"Thromb Haemost"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","article-title":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"397","author":"M Galli","year":"2021","journal-title":"Lancet"},{"key":"ref4","first-page":"103964","article-title":"Does individualized guided selection of antiplatelet therapy improve outcomes after percutaneous coronary intervention? A systematic review and meta-analysis","volume":"79","author":"N Yamani","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"issue":"04","key":"ref5","first-page":"628","article-title":"Why have studies of tailored anti-platelet therapy failed so far?","volume":"110","author":"J M Siller-Matula","year":"2013","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref6","first-page":"259","article-title":"Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls","volume":"11","author":"M P Winter","year":"2015","journal-title":"Postepy Kardiol Interwencyjnej"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/tpj.2015.70","article-title":"Interethnic variation of CYP2C19 alleles, \u2018predicted\u2019 phenotypes and \u2018measured\u2019 metabolic phenotypes across world populations","volume":"16","author":"I Fricke-Galindo","year":"2016","journal-title":"Pharmacogenomics J"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/ATVBAHA.118.311963","article-title":"Clinical utility of CYP2C19 genotyping to guide antiplatelet therapy in patients with an acute coronary syndrome or undergoing percutaneous coronary intervention","volume":"39","author":"M D Klein","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"991646","DOI":"10.3389\/fcvm.2022.991646","article-title":"Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy","volume":"9","author":"A B Nguyen","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17425255.2023.2178895","article-title":"Pharmacogenomics in Asians: differences and similarities with other human populations","volume":"19","author":"M Biswas","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"06","key":"ref11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jcin.2008.09.004","article-title":"Clopidogrel 150\u2009mg\/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study","volume":"1","author":"B Aleil","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"issue":"25","key":"ref12","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.jacc.2010.12.047","article-title":"Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome","volume":"57","author":"G Campo","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jacc.2014.03.051","article-title":"Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial","volume":"64","author":"W Hochholzer","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijcard.2017.03.074","article-title":"Prediction of high on-treatment platelet reactivity in clopidogrel-treated patients with acute coronary syndromes","volume":"240","author":"G M Podda","year":"2017","journal-title":"Int J Cardiol"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1055\/s-0038-1677549","article-title":"Diurnal variability of on-treatment platelet reactivity in clopidogrel versus prasugrel treated acute coronary syndrome patients: a pre-specified TROPICAL-ACS sub-study","volume":"119","author":"M K Freynhofer","year":"2019","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1540-8183.2011.00670.x","article-title":"Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention","volume":"24","author":"M A Gaglia","year":"2011","journal-title":"J Interv Cardiol"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/09537104.2013.840363","article-title":"Poor agreement between light transmission aggregometry, Verify Now P2Y12 and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials","volume":"25","author":"G Lemesle","year":"2014","journal-title":"Platelets"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/1074248420968706","article-title":"Comparison of light transmission aggregometry with impedance aggregometry in patients on potent P2Y12 inhibitors","volume":"26","author":"P P Wadowski","year":"2021","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"899594","DOI":"10.3389\/fcvm.2022.899594","article-title":"A sticky situation: variable agreement between platelet function tests used to assess anti-platelet therapy response","volume":"9","author":"H Nakahara","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"20","key":"ref20","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"S D Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"L Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1538-7836.2011.04216.x","article-title":"Clopidogrel 150 vs. 75\u2009mg day(-1) in patients undergoing percutaneous coronary intervention: a meta-analysis","volume":"9","author":"P P Hao","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref23","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1161\/CIRCGENETICS.114.000669","article-title":"CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis","volume":"7","author":"M J Sorich","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2217\/pgs-2021-0098","article-title":"Effects of the CYP2C19 LoF allele on major adverse cardiovascular events associated with clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis","volume":"23","author":"M Biswas","year":"2022","journal-title":"Pharmacogenomics"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"d4588","DOI":"10.1136\/bmj.d4588","article-title":"Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis","volume":"343","author":"T Bauer","year":"2011","journal-title":"BMJ"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2216-5263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T16:59:28Z","timestamp":1730825968000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2216-5263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":25,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2024,5,24]]},"published-print":{"date-parts":[[2024,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2216-5263","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,22]]},"published":{"date-parts":[[2023,11,22]]}}}